Astatine-211 PTT ([²¹¹At]PTT)

Astatine-211-Parthanatine ([²¹¹At]PTT), is an alpha-emitting radiotherapeutic which uses our small molecule PARPi platform to deliver a cytotoxic radioactive charge directly to the PARP-1 tumor cell nucleus, killing the cancer cell by creating lethal, double stranded DNA breaks.  The PARPi platform allows [²¹¹At]PTT to deliver a highly targeted alpha particle directly to the cell nucleus in the (NAD+) binding site for PARP-1 bound to DNA which is over expressed in many cancer cells.  [²¹¹At]PTT is in the preclinical phase with in vitro and in vivo research in neuroblastoma and glioblastoma.  [¹⁸F]FTT and [²¹¹At]PTT are close chemical analogs with similarly high affinity for PARP-1, making them an ideal diagnostic/therapeutic pair, ideal for guiding targeted radiopharmaceutical therapy.

[²¹¹At]PTT Publications